SalMar (OB:SALM) has drawn fresh attention after reporting consolidated operating results for the third quarter of 2026. The company reported a total harvest volume of 105,100 tonnes across its salmon farming operations.
SalMar's latest harvest update landed against a mixed price backdrop, with the share price at NOK554.0 after a 1-day share price return of 1.74%, but a year-to-date share price return that is down 10.50%, while the 3-year total shareholder return of 15.87% points to longer term holders seeing a very different experience from recent short term weakness.
Scan how SalMar compares with other aquaculture and food producers by running through our curated list of 620 high quality undiscovered gems that may be flying under most investors' radar.
Operationally, SalMar appears to be a solid salmon producer, yet the share price is still working off this year's drawdown. Is that recent weakness offering fair entry terms, or simply reflecting a valuation that is already fully priced in?
Most Popular Narrative: 10% Undervalued
At a last close of NOK554 and a widely followed fair value estimate of NOK615.45, the current pricing leaves SalMar trading at a material discount to what that narrative considers reasonable, with the gap tied directly to how the business is executing on costs, biology and new Norwegian capacity.
SalMar is focused on strengthening its value chain by investing in fish welfare and reducing costs, and the reported reductions in Norwegian ongrowth costs together with record biological performance in 2026 point to further potential support for net margins and earnings.
The company is implementing preventive and submerged technology to manage lice pressure, and the strong biological KPIs reported in the first seven months of 2026 suggest that continued refinement of these methods could help sustain lower mortality and higher growth, which can support profitability per kilo.
See why 17 investors see SalMar as 10% undervalued .
Result: Fair Value of NOK615.45 (UNDERVALUED)
Still, the bullish SalMar narrative leans heavily on Norwegian biology holding up, while environmental issues, rising production taxes and Icelandic losses do not deepen or spread.
Find out about the key risks to this SalMar narrative .
Another View: Valuing SalMar Through Market Multiples
The first narrative leans on cash flow and fair value estimates, but the plain P/E comparison tells a different story. SalMar trades on 34.3x earnings, well above the European Food sector on 15.5x and above its own fair ratio of 24.6x. That gap points to meaningful valuation risk if sentiment cools.
Before leaning too heavily on either story, it helps to see how the current P/E stacks up against detailed peer checks and the fair ratio our models suggest the market could move towards. You can do this by reviewing the See what the numbers say about this price — find out in our valuation breakdown. .
Visualising that relative pricing against sector peers with the
can make it easier to judge whether you see stretched expectations or a premium you are comfortable paying.
Next Steps
Sentiment around SalMar is clearly split, with both concern and optimism in play. Move fast, review the data yourself, and weigh up the 3 key rewards and 1 important warning sign .
Looking for more investment ideas beyond SalMar?
If SalMar has caught your attention, do not stop here. Broaden your watchlist with a few focused stock ideas tailored to different investing angles.
-
Chase potential mispricing by scanning the 185 high quality undervalued stocks that combine quality fundamentals with market pessimism that may have gone too far.
-
Build a steadier income stream by reviewing the 223 dividend fortresses that pair higher yields with more resilient payout histories.
-
Prioritise capital protection first by filtering for the 225 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SALM.OL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
